Analysis of retest reliability for pregnant women undergoing cfDNA testing with a no-call result
Molecular Biology Reports · 2023
DOI: 10.1007/s11033-023-08591-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2023. Verfasst von Shuqiong He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Genetic Diagnosis and Therapy Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology an…. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Abortion, Spontaneous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Startup Fund for scientific research, Fujian Medical University.
Abstract (Originalsprache)
Background
Determining the reasons for unreportable or no-call cell-free DNA (cfDNA) test results has been an ongoing issue, and a consensus on subsequent management is still lacking. This study aimed to explore potential factors related to no-call cfDNA test results and to discuss whether retest results are reliable. Methods and results This was a retrospective study of women with singleton pregnancies undergoing cfDNA testing in 2021. Of the 9871 pregnant patients undergoing cfDNA testing, 111 had a no-call result, and their results were compared to those of 170 control patients. The no-call rate was 1.12% (111/9871), and the primary cause for no-call results was data fluctuation (88.29%, 98/111). Medical conditions were significantly more frequent in the no-call group than in the reportable results group (P < 0.001). After retesting, 107 (107/111, 96.40%) patients had a result, and the false-positive rate (FPR) of retesting was 10.09% (10.09%, 11/109). In addition, placental lesions were more frequent in the no-call group than in the reportable results group (P = 0.037), and 4 patients, all in the no-call group, experienced pregnancy loss.
Conclusions
Pregnant women with medical conditions are more likely to have a no-call result. A retest is suggested for patients with a no-call result, but retests have a high FPR. In addition, pregnant women with a no-call result are at increased risk of adverse pregnancy outcomes. In conclusion, more attention should be given to pregnant women for whom a no-call cfDNA result is obtained.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Genetic Diagnosis and Therapy Center, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Key Laboratory for Prenatal Diagnosis and Birth D…
Förderung
- Natural Science Foundation of Fujian Province
- Startup Fund for scientific research, Fujian Medical University
Zitieren
APA
He, S., Zhang, Q., Chen, M., Chen, X., Liang, B., Lin, N., Huang, H., & Xu, L. (2023). Analysis of retest reliability for pregnant women undergoing cfDNA testing with a no-call result. Molecular Biology Reports. https://doi.org/10.1007/s11033-023-08591-2
Vancouver
He S, Zhang Q, Chen M, Chen X, Liang B, Lin N, et al. Analysis of retest reliability for pregnant women undergoing cfDNA testing with a no-call result. Molecular Biology Reports. 2023. doi:10.1007/s11033-023-08591-2
BibTeX
@article{He2023,
author = {He, Shuqiong and Zhang, Qian and Chen, Meihuan and Chen, Xuemei and Liang, Bin and Lin, Na and Huang, Hailong and Xu, Liangpu},
title = {Analysis of retest reliability for pregnant women undergoing cfDNA testing with a no-call result},
journal = {Molecular Biology Reports},
year = {2023},
doi = {10.1007/s11033-023-08591-2}
}
EUVIMED